LANOXIN

This brand name is authorized in Australia, Cyprus, Hong Kong, Ireland, Israel, Lithuania, Malta, Mexico, Netherlands, New Zealand, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug LANOXIN contains one active pharmaceutical ingredient (API):

1 Digoxin UNII 73K4184T59 - DIGOXIN

Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect. Read about Digoxin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LANOXIN Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR
LANOXIN Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
Lanoxin 125 Tablets	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C01AA05	Digoxin	C Cardiovascular system → C01 Cardiac therapy → C01A Cardiac glycosides → C01AA Digitalis glycosides
Discover more medicines within C01AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 1322N, 2605D, 3164M
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 104259, 13615, 13641, 13665, 14280, 161967, 175676, 185886, 27766
Country: HK	Department of Health Drug Office	Identifier(s): 03780, 03795, 03798, 60869
Country: IE	Health Products Regulatory Authority	Identifier(s): 30570, 30597, 30627, 63649
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 1110
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1089040, 1090989
Country: MT	Medicines Authority	Identifier(s): AA1343/00601, AA565/02904, MA955/00701, MA955/00702, PI1438/03201A, PI1438/03202A
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 28448
Country: NL	Z-Index G-Standaard	Identifier(s): 12129232, 12400378
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 15954, 1635, 5916, 5924, 5932
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 660, 661, 662
Country: SG	Health Sciences Authority	Identifier(s): 00544P, 00547P, 01198P, 01203P
Country: US	FDA, National Drug Code	Identifier(s): 59212-240, 59212-242, 59212-249, 70515-260, 70515-261, 70515-262, 70515-263, 71610-019
Country: ZA	Health Products Regulatory Authority	Identifier(s): J/6.3/302